RECRUITINGPhase 1INTERVENTIONAL
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
BCMA-CD19 cCAR in Relapsed and /or Refractory Multiple Myeloma and Plasmacytoid Lymphoma
About This Trial
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Who May Be Eligible (Plain English)
Who May Qualify:
- Signed written willing to sign a consent form; Patients volunteer to participate in the research
- Diagnosis is mainly based on the World Health Organization (WHO) 2008
- Patients have exhausted standard therapeutic options
- Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks
- Female must be not pregnant during the study
Who Should NOT Join This Trial:
- Patients declining to consent for treatment
- Prior solid organ transplantation
- Potentially curative therapy including chemotherapy or hematopoietic cell transplant
- Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Signed written informed consent; Patients volunteer to participate in the research
* Diagnosis is mainly based on the World Health Organization (WHO) 2008
* Patients have exhausted standard therapeutic options
* Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks
* Female must be not pregnant during the study
Exclusion Criteria:
* Patients declining to consent for treatment
* Prior solid organ transplantation
* Potentially curative therapy including chemotherapy or hematopoietic cell transplant
* Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents
Treatments Being Tested
BIOLOGICAL
BCMA-CD19 cCAR T cells
BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
Locations (2)
Peking University Shenzhen Hospital, China
Shenzhen, Guangdong, China
Chengdu Military General Hospital
Chengdu, Sichuan, China